A fast, free, service from the Kidney Cancer Association and EmergingMed
Ongoing clinical trials were discussed by Dr Jason Muhitch, who spoke about the AGS-003 immunotherapy trial (discussed in this blog post) and the potential of high-dose radiation to bolster anti-tumour immune responses, and Dr Namita Chittoria who discussed trials for papillary RCC caused by MET mutations.
Expression levels of a key protein involved in tumor cell survival appear to predict response to standard first-line therapy in patients with metastatic clear cell renal cell carcinoma...
A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check...
Each 10 mm increment in tumor burden prior to second-line therapy was associated with a significant 2.6% increased risk of death...
Cancer patients who regularly take aspirin, were found to have a "significant survival benefit" compared with those who do not, in a major study analyzing data from nearly 14,000 patients.
CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE)
Current treatments for advanced or metastatic RCC (mRCC) are associated with limited overall survival (OS) in previously treated patients. NIVO, a programmed death-1 (PD-1) immune checkpoint inhibitor, demonstrated encouraging OS and manageable safety in a phase II study in previously treated patients with mRCC (J Clin Oncol 2015;33:1430–7). This phase III study compared NIVO vs EVE in RCC after prior anti-angiogenic treatment...
Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-ta
Lenvatinib (LEN) – n oral inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT – in combination with everolimus (EVE) improved median progression-free survival (PFS; 14.6 mo) vs EVE (5.5 mo; hazard ratio [HR] 0.40; 95% confidence interval [CI] 0.24–0.68; P<0.001) or LEN (7.4 mo; HR 0.66; 95%CI 0.39–1.10; P=0.121) in a randomized, 3-arm, phase 2 study of patients with metastatic renal cell carcinoma (mRCC) following 1 VEGF-targeted therapy. In an updated analysis, LEN/EVE also showed an overall survival (OS) benefit vs EVE (HR 0.51; 95%CI 0.30–0.88; P=0.024). Here, we examine potential prognostic and predictive biomarkers from this study.
Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial
Nivolumab, a programmed death-1 immune checkpoint inhibitor, demonstrated encouraging overall survival (OS) and manageable safety in previously treated patients (pts) with metastatic renal cell carcinoma (mRCC) in a randomized phase 2 dose-ranging trial (NCT01354431). Median OS was 18.2–25.5 months (Motzer RJ, et al. J Clin Oncol, 2014). As response patterns with immunotherapy differ from those with chemotherapy, some pts may benefit from continued treatment with immunotherapy after initial evidence of RECIST-defined progression (Wolchok JD, et al. Clin Cancer Res, 2009). We present efficacy and safety in a subset of pts who were treated with nivolumab beyond RECIST-defined progression to investigate the potential benefits of this treatment approach.
New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model has been validated for patients (pts) with mRCC in the second line TT setting. This model does not consider time from 1st to 2nd line therapy, tumor shrinkage during 1st line and tumor burden before 2nd line. We sought to investigate these factors in addition to IMDC ones.